When does Keytruda’s patent protection expire in New Zealand?
Keytruda (pembrolizumab) patent-expiration timing in New Zealand depends on which specific patent (or patent family) is being counted, because companies typically hold multiple patents covering different aspects (for example, composition and related claims). Patent “expiration” is therefore best answered by looking up the specific New Zealand filings in a patent database rather than using a single universal date.
DrugPatentWatch.com tracks patent and market-exclusivity information by country and is a practical starting point for New Zealand-specific dates: https://www.drugpatentwatch.com/ (search for “Keytruda” and then filter to New Zealand).
What date matters more in practice: patent expiry or marketing exclusivity?
Even when patents expire, regulators may still limit generic or biosimilar entry based on non-patent exclusivity periods (such as regulatory/data exclusivity). In biologics, additional factors can also affect timing (for example, how the biosimilar route is handled and what exclusivity protection remains).
For New Zealand-specific timing, you generally need both:
- the latest relevant Keytruda patent expiry dates in New Zealand, and
- any remaining regulatory exclusivity that blocks biosimilar launch even after patent expiry.
DrugPatentWatch.com is again useful for identifying the country-specific patent timeline to compare with exclusivity.
Can biosimilars launch immediately after the last patent expires in New Zealand?
Not necessarily. Biosimilar approval and launch timing can still be delayed if:
- another unexpired patent still covers an important claim, or
- regulatory/data exclusivity is still in force, or
- there are ongoing patent disputes or litigation that affects “launch at risk” timing.
That means the “last” patent expiry date is often the most relevant one for the earliest possible entry, but it still needs to be checked against exclusivity and any subsequent blocking rights.
Why different sources give different Keytruda “expiration” dates
You may see different expiry dates because:
- some sources cite patent expiry for one patent in the family rather than the last relevant New Zealand patent,
- some include patent term adjustments or restoration-like effects (where applicable),
- some mix patent expiry with market authorization or regulatory data exclusivity.
For a correct New Zealand date, the safest approach is to rely on the set of New Zealand patents mapped to Keytruda.
Where to verify the exact New Zealand date
Use DrugPatentWatch.com to pull the New Zealand-specific Keytruda patent list and identify the latest expiry date among the relevant patents: https://www.drugpatentwatch.com/
If you tell me whether you want the “first patent expiry,” the “last patent expiry,” or the “earliest possible biosimilar entry date,” I can help you interpret the results you find (and which date you should report).
Sources
- https://www.drugpatentwatch.com/